Ohr Pharmaceuticals (NASDAQ: OHRP) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.


This table compares Ohr Pharmaceuticals and Compugen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ohr Pharmaceuticals N/A -103.56% -85.09%
Compugen N/A -70.91% -60.92%

Risk & Volatility

Ohr Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Compugen has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Institutional & Insider Ownership

8.4% of Ohr Pharmaceuticals shares are held by institutional investors. Comparatively, 18.5% of Compugen shares are held by institutional investors. 17.4% of Ohr Pharmaceuticals shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Ohr Pharmaceuticals and Compugen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ohr Pharmaceuticals N/A N/A -$25.76 million ($0.57) -2.77
Compugen $710,000.00 201.64 -$31.50 million ($0.71) -3.94

Ohr Pharmaceuticals has higher earnings, but lower revenue than Compugen. Compugen is trading at a lower price-to-earnings ratio than Ohr Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Ohr Pharmaceuticals and Compugen, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ohr Pharmaceuticals 0 0 2 0 3.00
Compugen 0 0 1 0 3.00

Ohr Pharmaceuticals currently has a consensus price target of $8.50, suggesting a potential upside of 437.97%. Compugen has a consensus price target of $14.00, suggesting a potential upside of 400.00%. Given Ohr Pharmaceuticals’ higher probable upside, equities analysts clearly believe Ohr Pharmaceuticals is more favorable than Compugen.


Ohr Pharmaceuticals beats Compugen on 6 of the 10 factors compared between the two stocks.

Ohr Pharmaceuticals Company Profile

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Compugen Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.